Clinical Trial Update: APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors [Phase 2]

View source ↗

Summary

Phase 2 study evaluating APL-101 in non-small cell lung cancer with MET exon 14 skipping mutations and MET dysregulation, as well as other MET-driven advanced s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma
• Glioblastoma
• Non-small Cell Lung Cancer
• Pancreatic Cancer
• Renal Cell Carcinoma
• Thyroid Cancer

Drugs mentioned

• APL-101

Snippet

Sponsor: Apollomics Inc. | Conditions: Solid Tumors, Advanced Cancer | Phase 2 | Status: RECRUITING